Citations

Mayo Clinic

Showing 10 of 108599 citations.

Technologies in pediatric vascular access: have we improved success rate in peripheral vein cannulation?
Haile, Dawit T. , Suominen, Pertti , Suominen, P K

Acta Anaesthesiologica Scandinavica | June 1, 2017 | Volume: 61 | Issue: 7 | Pages: 710-713

10.1111/aas.12916 | PMID 28567816 Get It

Heart Rate and Rhythm Disorders
Wackel, Philip L. , Cannon, Bryan C. , Wackel, Philip, Cannon, Bryan

Pediatrics In Review | June 1, 2017 | Volume: 38 | Issue: 6 | Pages: 243-253

10.1542/pir.2016-0119 | PMID 28572133 Get It

Is the Human Zygote a Person?
Nelson, Thomas K., Nelson, Thomas

The Linacre Quarterly | June 1, 2017 | Volume: 72 | Issue: 4 | Pages: 281-293

10.1080/20508549.2005.11877761 | PMID 16471031 Get It

Insulin differentially affects the distribution kinetics of amyloid beta 40 and 42 in plasma and brain
Swaminathan, Suresh Kumar, Ahlschwede, Kristen M. , Sarma, Vidur , Curran, Geoffry L., Omtri, Rajesh S. , Decklever, Teresa, Lowe, Val J. , Poduslo, Joseph F., Kandimalla, Karunya K. , Kandimalla, Karunya K

Journal of Cerebral Blood Flow & Metabolism | June 1, 2017 | Volume: 38 | Issue: 5 | Pages: 904-918

10.1177/0271678x17709709 | PMID 28569090 Get It

Impaired brain clearance of amyloid-beta peptides (Aβ) 40 and 42 across the blood–brain barrier (BBB) is believed to be one of the pathways responsible for Alzheimer’s disease (AD) pathogenesis. Hyperinsulinemia prevalent in type II diabetes was shown to damage cerebral vasculature and increase Aβ accumulation in AD brain. However, there is no clarity on how aberrations in peripheral insulin levels affect Aβ accumulation in the brain. This study describes, for the first time, an intricate relation between plasma insulin and Aβ transport at the BBB. Upon peripheral insulin administration in wild-type mice: the plasma clearance of Aβ40 increased, but Aβ42 clearance reduced; the plasma-to-brain influx of Aβ40 increased, and that of Aβ42 reduced; and the clearance of intracerebrally injected Aβ40 decreased, whereas Aβ42 clearance increased. In hCMEC/D3 monolayers (in vitro BBB model) exposed to insulin, the luminal uptake and luminal-to-abluminal permeability of Aβ40 increased and that of Aβ42 reduced; the abluminal-to-luminal permeability of Aβ40 decreased, whereas Aβ42 permeability increased. Moreover, Aβ cellular trafficking machinery was altered. In summary, Aβ40 and Aβ42 demonstrated distinct distribution kinetics in plasma and brain compartments, and insulin differentially modulated their distribution. Cerebrovascular disease and metabolic disorders may disrupt this intricate homeostasis and aggravate AD pathology.
PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins
Pérez‐Soriano, Alexandra , Arena, Julieta , Dinelle, Katie , Miao, Qing , McKenzie, Jessamyn , Neilson, Nicole, Puschmann, Andreas , Schaffer, Paul , Shinotoh, Hitoshi , Smith‐Forrester, Jenna, Shahinfard, Elham , Vafai, Nasim, Wile, Daryl , Wszolek, Zbigniew, Higuchi, Makoto , Stoessl, A. Jon , Wszołek, Zbigniew K. , Sossi, Vesna , Puschmann, Andreas

Movement Disorders | June 1, 2017 | Volume: 32 | Issue: 7 | Pages: 1016-1024

10.1002/mds.27029 | PMID 28568506 Get It

ABSTRACTBackground and Objectives: To study selective regional binding for tau pathology in vivo, using PET with [11C]PBB3 in PSP patients, and other conditions not typically associated with tauopathy.Methods: Dynamic PET scans were obtained for 70 minutes after the bolus injection of [11C]PBB3 in 5 PSP subjects, 1 subject with DCTN1 mutation and PSP phenotype, 3 asymptomatic SNCA duplication carriers, 1 MSA subject, and 6 healthy controls of similar age. Tissue reference Logan analysis was applied to each region of interest using a cerebellar white matter reference region.Results: In comparison to the control group, PSP subjects showed specific uptake of [11C]PBB3 in putamen, midbrain, GP, and SN. Longer disease duration and more advanced clinical severity were generally associated with higher tracer retention. A DCTN1/PSP phenotype case showed increased binding in putamen, parietal lobe, and GP. In SNCA duplication carriers, there was a significant increase of [11C] PBB3 binding in GP, putamen, thalamus, ventral striatum, SN, and pedunculopontine nucleus. The MSA case showed increased binding in frontal lobe, GP, midbrain, parietal lobe, putamen, temporal lobe, SN, thalamus, and ventral striatum.Conclusions: All PSP patients showed increased retention of the tracer in the basal ganglia, as expected. Binding was also present in asymptomatic SNCA duplication carriers and in an MSA case, which are not typically associated with pathological tau deposition. This suggests the possibility that [11C]PBB3 binds to alpha‐synuclein. © 2017 International Parkinson and Movement Disorder Society
The prognostic significance of polyclonal bone marrow plasma cells in patients with relapsing multiple myeloma
Ghosh, Toshi, Gonsalves, Wilson I. , Jevremović, Dragan , Dingli, David , Timm, Michael, Morice, William G. , Kapoor, Prashant , Kourelis, Taxiarchis , Lacy, Martha Q. , Hayman, Suzanne R. , Lin, Yi , Russell, Stephen J. , Lust, John A., Zeldenrust, Steven R., Warsame, Rahma , Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Timm, Michael M, Kourelis, Taxiarchis V, Buadi, Francis K. , Leung, Nelson , Go, Ronald S , Warsame, Rahma , Dispenzieri, Angela , Morice, William George , Leung, Nelson , Go, Ronald S. , Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson , Russell, Stephen J , Jevremovic, Dragan , Dingli, David , Lin, Yi

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24807 | PMID 28568244 Get It

AbstractPrior studies have revealed that the presence of increasing number of polyclonal plasma cells (pPCs) in the bone marrow (BM) are associated with better outcomes in newly diagnosed multiple myeloma (MM) patients. This effect has not been studied in patients with MM at the time of disease relapse. We determined the prognostic value of depletion of pPCs in the BM by 7‐color multiparameter flow cytometry in a series of 174 relapsing MM patients. The time to next therapy (TTNT) in those with <5% pPCs was 9.4 months versus 13.9 months in those with ≥5% pPCs (P = .0091). The median overall survival (OS) in those with <5% pPCs was 21.4 months, while the median OS was not reached in those patients with ≥5% pPCs (P = .019). Of the 109 patients with standard risk cytogenetics, the median OS of those with <5% pPCs was 28.4 months, while the median OS was not reached in those with ≥5% pPCs (P = .033). As such, <5% pPCs in the BM appears to have prognostic utility in identifying a subset of relapsing MM patients, even with standard‐risk cytogenetics, who have a particularly adverse outcome.
A follow‐up on desiderosmia (olfactory craving), a novel symptom associated with iron deficiency anemia
Hansen, Bryar R. , Bottner, Wayne A., Ravindran, Aishwarya , DeJesus, Ramona S. , Go, Ronald S. , DeJesus, Ramona, Go, Ronald S , Ravindran, Aishwarya

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24806 | PMID 28568111 Get It

Cardiac tamponade in myelofibrosis: A Mayo clinic series of nine consecutive cases
Lavu, Sravanthi , Tefferi, Ayalew

American Journal of Hematology | June 1, 2017 | Volume: 92 | Issue: 9 | Pages: No page available

10.1002/ajh.24800 | PMID 28568842 Get It

Low Cryptococcus Antigen Titers as Determined by Lateral Flow Assay Should Be Interpreted Cautiously in Patients without Prior Diagnosis of Cryptococcal Infection
Dubbels, Marie, Granger, Dane, Theel, Elitza S.

Journal of Clinical Microbiology | June 1, 2017 | Volume: 55 | Issue: 8 | Pages: 2472-2479

10.1128/jcm.00751-17 | PMID 28566315 Get It

ABSTRACTDetection ofCryptococcusantigen (CrAg) is invaluable for establishing cryptococcal disease. Multiple different methods for CrAg detection are available, including a lateral flow assay (LFA). Despite excellent performance of the CrAg LFA, we have observed multiple cases of low-titer (≤1:5) positive CrAg LFA results in patients for whom cryptococcosis was ultimately excluded. To investigate the accuracy of low-titer positive CrAg LFA results, we performed chart reviews for all patients with positive CrAg LFA results between June 2014 and December 2016. During this period, serum and/or cerebrospinal fluid (CSF) samples from 3,969 patients were tested with the CrAg LFA, and 55 patients (1.5%) tested positive. Thirty-eight of those patients lacked a history of cryptococcal disease and were the focus of this study. Fungal culture or histopathology confirmedCryptococcusinfection for 20 patients (52.6%), and CrAg LFA titers in serum and CSF samples ranged from 1:5 to ≥1:2,560. For the 18 patients (47.4%) without culture or histopathological confirmation, the CrAg LFA results were considered true-positive results for 5 patients (titer range, 1:10 to ≥1:2,560), due to clinical improvement with targeted therapy and decreasing CrAg LFA titers. The remaining 13 patients had CrAg LFA titers of 1:2 (n= 11) or 1:5 (n= 2) and were ultimately diagnosed with an alternative condition (n= 11) or began therapy for possible cryptococcosis without improvement (n= 2), leading to an overall CrAg LFA false-positive rate of 34%. We recommend careful clinical correlation prior to establishing a diagnosis of cryptococcal infection for patients with first-time positive CrAg LFA titers of 1:2.
Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Cheung, Angela , Cheung, Angela C, Lazaridis, Konstantinos N. , LaRusso, Nicholas F. , Gores, Gregory J.

Seminars in Liver Disease | May 31, 2017 | Volume: 37 | Issue: 02 | Pages: 159-174

10.1055/s-0037-1603324 | PMID 28564724 Get It

AbstractEpigenomics, the study of modifications to genetic material that do not alter the underlying DNA sequence, is generating increasing interest as a means to help clarify disease pathogenesis and outcomes. Although genome-wide association studies have identified several potential candidate genes that may be implicated in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), it is estimated that these genes explain less than 20% of the heritability of these diseases. Thus, to date, the origins of “missing heritability” for PBC and PSC remain elusive. The epigenome may provide a potentially elegant solution to this phenomenon, as it can be modified by both internal and external exposures (coined the “exposome”). This may explain differences in disease presentation, treatment response, and rates of progression between individuals. Epigenetic changes may also provide a framework for discovering potential biomarkers for diagnosis and screening of PBC and PSC. Importantly, because the epigenome is modifiable, it may also highlight novel pathways for therapeutic discovery and interventions of these diseases.